Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Jiangbo Predicts $8-$12 Million First Year Sales of Hypertension Drug

publication date: Aug 17, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jiangbo Pharmaceuticals has received approval from the Shandong Food and Drug Administration to start selling a treatment for high blood pressure, Felodipine sustained release tablets. The company expects to sell $8 million to $12 million of the drug in the first 12 months at a 70% gross margin. More details...

Stock Symbol: (NSDQ: JGBO)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...